Merck Says Keytruda Sales Rose 6% to $8.6 Billion in Q3
Keytruda generated nearly half of Merck’s worldwide sales in the third quarter. Merck attributed the drug’s growth to uptake in earlier-stage indications and its new Qlex form.
Merck's blockbuster cancer treatment Keytruda generated nearly half of the company's total worldwide sales in the third quarter, with sales of the drug up 6% to $8.6 billion. Merck attributed the drug's growth to uptake in earlier-stage indications, as well as a new form of the drug called Qlex, wh…